Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04555811 · ClinicalTrials.gov registry record · Phase 1
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04555811 is a Phase 1 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 7 participants.
The verdict
NCT04555811, a Phase 1 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma.
Interventions
- DRUG Rituximab
- DRUG FT596
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-09-22 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04555811
The ClinicalTrials.gov registry entry for NCT04555811 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT04555811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04555811 about?
NCT04555811 is a clinical study titled "FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL". This is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma.
What is the current status of trial NCT04555811?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2020-09-22. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT04555811?
The interventions under investigation include: Rituximab (DRUG), FT596 (DRUG).
Who is sponsoring clinical trial NCT04555811?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.